CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04974684
NCT04974684N/ACompleted
CompareCT.gov

Direct Oral Anticoagulant Therapy With the HeartMate 3 LVAD: A Pilot Study

Institute for Clinical and Experimental Medicine·interventional·Posted Jul 23, 2021·Updated Aug 20, 2024

In Brief

A clinical study evaluating HeartMate 3 and Apixaban for LVAD (Left Ventricular Assist Device) Thrombosis. Completed, enrolled 45 participants across 1 site.

Detailed Summary

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLVAD (Left Ventricular Assist Device) Thrombosis
CountriesCzechia
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 23, 2021
Enrollment StartApr 1, 2022
Primary CompletionMar 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.9 years ago

Interventions

HeartMate 3device

Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.

Apixabandrug

Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.